Core Viewpoint - BioRestorative Therapies, Inc. has announced a change in the timing of its upcoming webcasted conference call to discuss its pipeline update, now scheduled for 10:30am EST on February 27, 2025 [1] Company Overview - BioRestorative Therapies, Inc. is focused on developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells [3] - The company has two core clinical development programs targeting disc/spine disease and metabolic disorders, along with a commercial BioCosmeceutical platform [3] Clinical Development Programs - Disc/Spine Program (brtxDISC): The lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells from the patient's bone marrow, intended for non-surgical treatment of painful lumbosacral disc disorders. A Phase 2 clinical trial has commenced to treat chronic lower back pain from degenerative disc disease [3][4] - Metabolic Program (ThermoStem): This program focuses on developing cell-based therapies targeting obesity and metabolic disorders using brown adipose derived stem cells (BADSC) to generate brown adipose tissue (BAT). Initial preclinical research suggests that increased brown fat may enhance caloric burning and reduce glucose and lipid levels [4] BioCosmeceuticals - BioRestorative operates a commercial BioCosmeceutical platform, with a current product that is a cell-based secretome designed to reduce fine lines and wrinkles. The company plans to expand its offerings to include a broader range of cell-based biologic aesthetic products and therapeutics, aiming for FDA approvals [5]
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update